Ken Griffin Humanigen, Inc Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.13 - $0.2 $3,173 - $4,882	24,410 Added 13869.32%	24,586 $3,000
Q1 2023 May 15, 2023	SELL	$0.12 - $0.23 $13,246 - $25,388	-110,384 Reduced 99.84%	176 $0
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $0 - $0	-2 Reduced -0.0%	110,560 $13,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $865 - $17,416	5,767 Added 5.5%	110,562 $20,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $157,298 - $297,615	-89,374 Reduced 46.03%	104,795 $185,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $452,367 - $992,210	-249,927 Reduced 56.28%	194,169 $584,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1.42 Million - $3.19 Million	388,416 Added 697.59%	444,096 $1.65 Million
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $157,632 - $264,739	-11,642 Reduced 17.29%	55,680 $967,000
Q1 2021 May 17, 2021	SELL	$12.91 - $23.83 $7.11 Million - $13.1 Million	-551,097 Reduced 89.11%	67,322 $1.29 Million
Q4 2020 Feb 16, 2021	SELL	$7.97 - $21.66 $5.56 Million - $15.1 Million	-697,472 Reduced 53.0%	618,419 $10.8 Million
Q3 2020 Nov 16, 2020	BUY	$8.0 - $28.5 $10.5 Million - $37.5 Million	1,315,891 New	1,315,891 $14 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.